Objective/background: Drug-resistant strains of tuberculosis (TB) represent a major threat to global TB control. In low- and middle-income countries, resource constraints make it difficult to identify and monitor cases of resistance using drug susceptibility testing and culture. Molecular assays such as the GeneXpert Mycobacterium tuberculosis/rifampicin may prove to be a cost-effective solution to this problem in these settings. The objective of this study is to evaluate the use of GeneXpert in the diagnosis of pulmonary TB since it was introduced into two tertiary hospitals in Ghana in 2013.
Methods: A 2-year retrospective audit of clinical cases involving patients who presented with clinically suspected TB or documented TB not improving on standard therapy and had samples sent for GeneXpert testing.
Results: GeneXpert identified 169 cases of TB, including 17 cases of rifampicin-resistant TB. Of the seven cases with final culture and drug susceptibility testing results, six demonstrated further drug resistance and five of these were multidrug-resistant TB.
Conclusion: These findings call for a scale-up of TB control in Ghana and provide evidence that the expansion of GeneXpert may be an optimal means to improve case finding and guide treatment of drug-resistant TB in this setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijmyco.2016.02.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Molecular Bacterial Load Assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif.
J Infect
December 2024
German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Division of Clinical Infectious Diseases, Research Center Borstel, Parkallee 1-40, 23845 Borstel, Germany.
Objectives: Early detection of treatment failure is essential to improve the management of drug-resistant tuberculosis (DR-TB). We evaluated the molecular bacterial load assay (MBLA) in comparison to standard diagnostic tests for monitoring therapy of patients affected by drug-resistant TB.
Methods: The performance of MBLA in tracking treatment response in a prospective cohort of patients with pulmonary MDR/RR- and pre-XDR/XDR-TB was compared with mycobacterial culture, mycobacterial DNA detection using GeneXpert (Xpert) and microscopy detection of sputum acid-fast-bacilli.
Prevalence, clinical characteristics, and treatment outcomes of childhood tuberculosis in Nigeria: a systematic review and meta-analysis.
BMC Infect Dis
December 2024
Department of Internal Medicine, Asokoro District Hospital, Abuja, Nigeria.
Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a leading cause of infection-related deaths worldwide. Children with underdeveloped immune systems are particularly vulnerable, experiencing symptoms akin to common childhood illnesses. Early diagnosis and treatment typically yield positive outcomes.
View Article and Find Full Text PDFClinical features of Tibetan adolescent tuberculosis at high altitudes: a retrospective study.
BMC Pulm Med
December 2024
Department of Respiratory Medicine, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, 518112, China.
Background: Adolescent pulmonary tuberculosis (TB) is considered inadequately recognized and underreported at high altitudes. This study aimed to investigate the clinical features of adolescent pulmonary TB patients at high altitudes in China.
Method: A retrospective analysis was performed at Linzhi People's Hospital.
Prevalence of non-tuberculous mycobacteria among people with acid-fast positive presumptive tuberculosis in Mali.
PLoS One
December 2024
Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Background: Non-tuberculous mycobacteria (NTM) are environmental agents that can cause opportunistic pulmonary disease in humans and animals, often misdiagnosed as tuberculosis (TB). In this study, we describe the cases of NTM identified during the first national anti-TB drug resistance survey conducted in Mali and explore associated risk factors.
Methods: Sputum was collected from people presenting for pulmonary TB diagnosis from April to December 2019, regardless of age.
Genotypes and drug resistance pattern of complex among clinically diagnosed pulmonary tuberculosis patients.
Front Public Health
December 2024
Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Background: Clinically diagnosed pulmonary tuberculosis (TB) (CDPTB) patients account for a huge proportion of TB. However, little is known about the genetic diversity and drug resistance profile of Complex (MTBC) strains in this group of patients.
Method: Unmatched case-control study was conducted among 313 PTB patients to compare the genetic diversity of MTBC and their drug resistance profiles among CDPTB ( = 173) and bacteriologically confirmed pulmonary TB (BCPTB) ( = 140) patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!